Patent application number | Description | Published |
20140116894 | Method and apparatus for monitoring alteration of flow characteristics in a liquid sample - A device for measuring blood coagulation time is formed from a first substrate; a second substrate; a spacer layer disposed between the first and second substrates, said spacer layer having an opening formed therein defining a sample receiving chamber, a vented sink chamber, and an elongated reservoir forming a conduit for liquid movement between the sample receiving chamber and the sink chamber; a first electrode disposed on the first substrate, said first electrode being exposed in the reservoir portion through a first opening in the spacer layer; and a second electrode disposed on the second substrate, said second electrode being exposed in the reservoir portion through a second opening in the spacer layer. The device of the invention is used in combination with an apparatus that is connected to the first and second electrodes for measuring current flow between the first and second electrodes. Changes in observed current are indicative of flow through the device, and a cessation of flow indicates coagulation. | 05-01-2014 |
20140231252 | Integrated Blood Glucose Measurement Device - A portable combination for measuring a glucose concentration value in a sample has a portable glucose meter (GM) having a test strip port for receiving a disposable electrochemical test strip, means for calculating a glucose concentration value in a sample applied to a test strip received in the test strip port, and optionally a rechargeable GM battery. Next the combination has a portable rechargeable supplemental battery pack (SBP). The combination also has a web enabled portable device (WEPD) having a rechargeable WEPD battery and a wireless connection to the Internet. The GM, the SBP, and the WEPD are electrically coupled to allow power transfer between the GM, the SBP, and the WEPD. The GM and the WEPD are communicatively coupled to allow for data transfer between the GM and the WEPD. The GM and SBP are detachable from and reattachable to the WEPD to form the portable combination. Lastly the combination has means for managing battery operations of the combination. These means are effective to cause the GM to draw operating power first from the SBP, second from the WEPD battery, and third from the GM battery, if the GM battery is present. | 08-21-2014 |
Patent application number | Description | Published |
20120225885 | IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to novel imidazole compounds, pharmaceutical compositions comprising the imidazole compounds and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: | 09-06-2012 |
20130045914 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS - In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 02-21-2013 |
20130225582 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS - In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 08-29-2013 |
20150353498 | SUBSTITUTED ISOQUINOLINES AS CRTH2 RECEPTOR MODULATORS - The invention provides certain substituted isoquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters. The invention also provides pharmaceutical compositions comprising for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function. | 12-10-2015 |
Patent application number | Description | Published |
20100190759 | NK 1 ANTAGONISTS - A compound having the general structure shown in Formula I: | 07-29-2010 |
20100227873 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF - The present invention provides compounds of Formula (I): | 09-09-2010 |
20110207734 | Azine Derivatives and Methods of Use Thereof - The present invention relates to Azine Derivatives, pharmaceutical compositions comprising the Azine Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. | 08-25-2011 |
20110251207 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS - In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 10-13-2011 |
20110319434 | Bicyclic Heterocyclic Derivatives and Methods of Use Thereof - The present invention relates to novel Bicyclic Heterocyclic Derivatives, pharmaceutical compositions comprising the Bicyclic Heterocyclic Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. | 12-29-2011 |
20120295879 | NK1 Antagonists - A compound having the general structure shown in Formula I: | 11-22-2012 |
20140296196 | NK1 ANTAGONISTS - A compound having the general structure shown in Formula I: | 10-02-2014 |
Patent application number | Description | Published |
20090003238 | Node Merging Process for Network Topology Representation - Node merging methods and apparatus are disclosed for generating simplified representations of network topology. A first topology representative of a given network is determined, and at least one pair of nodes of the first topology is merged into a single node based on measures associated with respective edges connecting the nodes of the node pair to at least one neighbor node common to that pair. The merging step is repeated for one or more additional pairs of nodes to produce a reduced network topology meeting one or more desired criteria, and a visualization or other representation of the reduced network topology is generated. | 01-01-2009 |
20090116397 | Network Condition Capture and Reproduction - A network condition capture and reproduction technique captures measurement data characterizing network conditions at a given time between first and second endpoint devices of a network, and utilizes the captured measurement data in a network impairment device to reproduce the network conditions at a later time and possibly in a different place. | 05-07-2009 |
20090122713 | Interfering Packet Streams in Packet Networks - A method for estimating the network-layer topology of a telecommunications network is described. In particular, the illustrative embodiment of the present invention estimates the existence and connectivity of nodes in the topology based on the detection of network-wide end-to-end path intersections. This is based on the assumption that pairs of streams of packets that share a common node will interfere and that the interference can be detected in the received streams. In general, this interference is manifested as jitter. By transmitting streams on each pair of end-to-end paths in the network, and detecting interference (or a lack of interference) a matrix of path intersections for the network can be created. Using logic and supposition, the topology of the network can be estimated using the matrix of path intersections. Once the estimate of the topology is complete, the maintenance and operation of the network can proceed based on the topology. | 05-14-2009 |
20090141647 | Acknowledgment of Media Waveforms between Telecommunications Endpoints - An apparatus and method are disclosed that enable a first telecommunications endpoint to ensure that a second endpoint is receiving the first endpoint's packet stream transmissions with a satisfactory waveform quality. When the second endpoint receives the packet stream, it decodes the media waveform from the stream, encodes the waveform back into a second packet stream, and transmits some or all of the packets in the second stream back to the first endpoint. The first endpoint then decodes the received waveform in the second stream and compares it to the original waveform transmitted to the second endpoint. Based on the comparison, the first endpoint adjusts the value of a quality indication, and provides the quality indication to its user and to the second endpoint. Advantageously, the user at the second endpoint is able to determine whether the received waveform is, in fact, close enough to the waveform that the first endpoint's user intended to be received and understood. | 06-04-2009 |
20090268622 | Route Tracing Program Configured to Detect Particular Network Element Making Type of Service Modification - One or more network elements that modify type of service values in a network are detected by sending route tracing messages having increasing time-to-live values and a designated type of service value from a first network element to a second network element. Type of service values are monitored in respective time exceeded messages received from respective network elements on a given network path between the first network element and the second network element responsive to the route tracing messages. At least a particular one of the network elements on the given network path that has made a modification in type of service value relative to the designated type of service value is identified, based on the monitored type of service values in the respective time exceeded messages. | 10-29-2009 |
Patent application number | Description | Published |
20090136946 | Automated Enumeration and Characterization of Circulating Melanoma Cells in Blood - The CellTracks® System provides a system to enumerate circulating melanoma cells in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies circulating melanoma cells. The absolute number of circulating melanoma cells detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. Diagnosis and monitoring of melanoma has been limited by the inability to monitor circulating melanoma cells. The present invention provides a method to enumerate circulating melanoma cells in blood samples. Accordingly, this technology provides a means and device for monitoring disease progression in patients with melanoma. | 05-28-2009 |
20090191535 | Method of assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells - A method for assessing cancer in test subjects is described based upon enumeration of circulating endothelial cells and/or disseminated tumor cells in a test subject. This method is used to quantify disseminated tumor cells. Correlations with circulating tumor cells provides prognostic information with high accuracy in assessing the risk of recurrence in patients with primary breast cancer. | 07-30-2009 |
20110104718 | Analysis of Circulating Tumor Cells, Fragments, and Debris - The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods. | 05-05-2011 |
20110300551 | METHOD OF PREDICTING CLINICAL OUTCOMES FOR MELANOMA PATIENTS USING CIRCULATING MELANOMA CELLS IN BLOOD - The present invention provides an automated method for capturing and detecting circulating melanoma cells (CMC's) in the blood of patients with melanoma. The absolute number of circulating melanoma cells detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. | 12-08-2011 |
20120094275 | METHODS AND KITS FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PANCREATIC PATIENTS USING POLYSPECIFIC CAPTURE AND COCKTAIL DETECTION REAGENTS - A highly sensitive assay is disclosed which combines immunomagnetic enrichment with multiparameter flow cytometric or image cytometry to detect, enumerate and characterize carcinoma cells in the blood. The present invention incorporates the conjugation of different antibodies to the same ferrofluid. This has the effect of making the ferrofluid polyspecific with respect to the antigens that the ferrofluid will bind. The multiple antibodies present on the same ferrofluid do not appear to block or otherwise interfere with each other. Such ferrofluids have the highly desirable effect of being able to bind specifically to more than one type of cell. The assay is especially useful to enable the capture of CTCs that have low EpCAM expression, but high expression of other tumor markers; Accordingly, the assay facilitates the biological characterization and staging of carcinoma cells. | 04-19-2012 |
20130157347 | Method of Analyzing Cardiovascular Disorders and Uses Thereof - Compositions, systems, and methods comprising circulating endothelial cells (CECs) are provided. The compositions described herein utilize isolated CECs, including compositions in a form that allows analysis of the CECs. The systems described herein utilize isolated CECs and an analytical tool or an output from an analytical tool. The methods described herein are related to the use of isolated CECs and analytical tools for providing information, to a health care provider or the CEC donor, that is relevant to the cardiovascular health of the CEC donor. Thus, the compositions, systems and methods described herein involve both a transformation (e.g., non-isolated CECs to isolated CECs, or isolated CECs to analyzed CECs) and a machine (e.g., isolation tools and analytical tools). | 06-20-2013 |
20140335542 | MOLECULAR CHARACTERIZATION OF CIRCULATING TUMOR CELLS - The disclosed invention includes methods and kits for the removal of white blood cells from samples of enriched rare cells. | 11-13-2014 |
20160077097 | METHOD OF ISOLATING CIRCULATING TUMOR CELLS - Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject. | 03-17-2016 |
Patent application number | Description | Published |
20130325130 | LATERAL ENTRY INSERT FOR CUP TRIAL - Trials for a reverse shoulder system are described. The trials generally include an insert housed within a humeral cup. The insert has a proximal end and a distal end, the proximal end having a concave recess therein adapted to receive a glenosphere prosthesis. The distal end of the insert includes a shaft, the shaft is substantially housed within the confines of the humeral cup. A distal end of the humeral cup is inserted in a humeral stem. | 12-05-2013 |
20130325133 | LATERAL ENTRY INSERT FOR CUP TRIAL - Trials for a reverse shoulder system are described. The trials generally include an insert housed within a humeral cup. The insert has a proximal end and a distal end, the proximal end having a concave recess therein adapted to receive a glenosphere prosthesis. The distal end of the insert includes a shaft, the shaft is substantially housed within the confines of the humeral cup. A distal end of the humeral cup is inserted in a humeral stem. | 12-05-2013 |
20130325134 | LATERAL ENTRY INSERT FOR CUP TRIAL - Trials for a reverse shoulder system are described. The trials generally include an insert housed within a humeral cup. The insert has a proximal end and a distal end, the proximal end having a concave recess therein adapted to receive a glenosphere prosthesis. The distal end of the insert includes a shaft, the shaft is substantially housed within the confines of the humeral cup. A distal end of the humeral cup is inserted in a humeral stem. | 12-05-2013 |
20140277190 | COMPRESSION SCREW WITH VARIABLE PITCH THREAD - A bone screw apparatus is provided for threaded engagement with a bone and, optionally, a medical device such as a bone plate. The bone screw has a shaft having a first end, a second end, and a first thread having a first pitch. The screw further includes a head having a proximal end, a distal end adjacent the shaft first end, and a second thread having a second pitch. The second thread has a variable pitch that increases in a proximal direction, but never exceeds the magnitude of any portion of the first pitch. Upon threaded engagement of the head with bone or a medical device, a compression force is generated which continuously decreases as the screw is further inserted. | 09-18-2014 |
Patent application number | Description | Published |
20140208072 | USER-LEVEL MANAGER TO HANDLE MULTI-PROCESSING ON MANY-CORE COPROCESSOR-BASED SYSTEMS - A method is disclosed to manage a multi-processor system with one or more multiple-core coprocessors by intercepting coprocessor offload infrastructure application program interface (API) calls; scheduling user processes to run on one of the coprocessors; scheduling offloads within user processes to run on one of the coprocessors; and affinitizing offloads to predetermined cores within one of the coprocessors by selecting and allocating cores to an offload, and obtaining a thread-to-core mapping from a user. | 07-24-2014 |
20140208327 | METHOD FOR SIMULTANEOUS SCHEDULING OF PROCESSES AND OFFLOADING COMPUTATION ON MANY-CORE COPROCESSORS - A method is disclosed to manage a multi-processor system with one or more manycore devices, by managing real-time bag-of-tasks applications for a cluster, wherein each task runs on a single server node, and uses the offload programming model, and wherein each task has a deadline and three specific resource requirements: total processing time, a certain number of manycore devices and peak memory on each device; when a new task arrives, querying each node scheduler to determine which node can best accept the task and each node scheduler responds with an estimated completion time and a confidence level, wherein the node schedulers use an urgency-based heuristic to schedule each task and its offloads; responding to an accept/reject query phase, wherein the cluster scheduler send the task requirements to each node and queries if the node can accept the task with an estimated completion time and confidence level; and scheduling tasks and offloads using a aging and urgency-based heuristic, wherein the aging guarantees fairness, and the urgency prioritizes tasks and offloads so that maximal deadlines are met. | 07-24-2014 |
20140208331 | METHODS OF PROCESSING CORE SELECTION FOR APPLICATIONS ON MANYCORE PROCESSORS - A runtime method is disclosed that dynamically sets up core containers and thread-to-core affinity for processes running on manycore coprocessors. The method is completely transparent to user applications and incurs low runtime overhead. The method is implemented within a user-space middleware that also performs scheduling and resource management for both offload and native applications using the manycore coprocessors. | 07-24-2014 |
20140237477 | SIMULTANEOUS SCHEDULING OF PROCESSES AND OFFLOADING COMPUTATION ON MANY-CORE COPROCESSORS - Methods and systems for scheduling jobs to manycore nodes in a cluster include selecting a job to run according to the job's wait time and the job's expected execution time; sending job requirements to all nodes in a cluster, where each node includes a manycore processor; determining at each node whether said node has sufficient resources to ever satisfy the job requirements and, if no node has sufficient resources, deleting the job; creating a list of nodes that have sufficient free resources at a present time to satisfy the job requirements; and assigning the job to a node, based on a difference between an expected execution time and associated confidence value for each node and a hypothetical fastest execution time and associated hypothetical maximum confidence value. | 08-21-2014 |
Patent application number | Description | Published |
20150212733 | SYSTEMS AND METHODS FOR SWAPPING PINNED MEMORY BUFFERS - Systems and methods for swapping out and in pinned memory regions between main memory and a separate storage location in a system, including establishing an offload buffer in an interposing library; swapping out pinned memory regions by transferring offload buffer data from a coprocessor memory to a host processor memory, unregistering and unmapping a memory region employed by the offload buffer from the interposing library, wherein the interposing library is pre-loaded on the coprocessor, and collects and stores information employed during the swapping out. The pinned memory regions are swapped in by mapping and re-registering the files to the memory region employed by the offload buffer, and transferring data of the offload buffer data from the host memory back to the re-registered memory region. | 07-30-2015 |
20160110134 | Large-Scale, Dynamic Graph Storage and Processing System - A graph storage and processing system is provided. The system includes a scalable, distributed, fault-tolerant, in-memory graph storage device for storing base graph data representative of graphs. The system further includes a real-time, in memory graph storage device for storing update graph data representative of graph updates for the graphs with respect to a time threshold. The system also includes an in-memory graph sampler for sampling the base graph data to generate sampled portions of the graphs and for storing the sampled portions of the graph. The system additionally includes a query manager for providing a query interface between applications and the system and for forming graph data representative of a complete graph from at least the base graph data and the update graph data, if any. The system also includes a graph computer for processing the sampled portions using batch-type computations to generate approximate results for graph-based queries. | 04-21-2016 |
20160110404 | Real-time Abnormal Change Detection in Graphs - A method is provided for detecting abnormal changes in real-time in dynamic graphs. The method includes extracting, by a graph sampler, an active sampled graph from an underlying base graph. The method further includes merging, by a graph merger, the active sampled graph with graph updates within a predetermined recent time period to generate a merged graph. The method also includes computing, by a graph diameter computer, a diameter of the merged graph. The method additionally includes determining, by a graph diameter change determination device, whether a graph diameter change exists. The method further includes generating, by an alarm generator, a user-perceptible alarm responsive to the graph diameter change. | 04-21-2016 |
20160110409 | Large-Scale, Dynamic Graph Storage and Processing System - A method in a graph storage and processing system is provided. The method includes storing, in a scalable, distributed, fault-tolerant, in-memory graph storage device, base graph data representative of graphs, and storing, in a real-time, in memory graph storage device, update graph data representative of graph updates for the graphs with respect to a time threshold. The method further includes sampling the base graph data to generate sampled portions of the graphs and storing the sampled portions, by an in-memory graph sampler. The method additionally includes providing, by a query manager, a query interface between applications and the system. The method also includes forming, by the query manager, graph data representative of a complete graph from at least the base graph data and the update graph data, if any. The method includes processing, by a graph computer, the sampled portions using batch-type computations to generate approximate results for graph-based queries. | 04-21-2016 |
Patent application number | Description | Published |
20100028427 | IMMEDIATE RELEASE FORMULATIONS OF 1-AMINOCYCLOHEXANE COMPOUNDS, MEMANTINE AND NERAMEXANE - The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average T | 02-04-2010 |
20110236439 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane - The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average T | 09-29-2011 |
20120004318 | MODIFIED RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS - The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment. | 01-05-2012 |
20120201889 | MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE - The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain. | 08-09-2012 |
20130011474 | MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE - The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain. | 01-10-2013 |
20130012593 | MODIFIED RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS - The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions, following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment. | 01-10-2013 |
20130302430 | MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE - The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain. | 11-14-2013 |
20130310460 | MODIFIED RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS - The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment. | 11-21-2013 |
20140213659 | MODIFIED RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS - The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment. | 07-31-2014 |
20140348932 | IMMEDIATE RELEASE FORMULATIONS OF 1-AMINOCYCLOHEXANE COMPOUNDS, MEMANTINE AND NERAMEXANE - The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average T | 11-27-2014 |
20150148427 | MODIFIED RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS - The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment. | 05-28-2015 |
20150258031 | MODIFIED RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS - The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment. | 09-17-2015 |
20150258042 | MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE - The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain. | 09-17-2015 |
Patent application number | Description | Published |
20110106731 | QUESTIONNAIRE GENERATION - A questionnaire generation process presents a first subset from a set of questions of the questionnaire and receives first answers from a user. The first answers are used to determine whether the first answers are sufficient to give definite values to conditions of first rules, wherein the first rules have conditions for providing output. When the first answers are not sufficient, the conditions of the first rules can be used to identify a second subset of the questions, wherein the second subset of questions has second answers such that a combination of the first and second answers is sufficient to give definite values to the respective conditions of the first rules, and the second subset of questions can be presented to the user. | 05-05-2011 |
20130117075 | PROJECT COMPLIANCE ASSESSMENT - Compliance of a project is assessed by generating a graph including nodes representing attributes of the project, and populating a subset of nodes in the graph with attribute values of the project. A rule applicable to the subset of nodes is identified and applied to determine whether the attribute values comply with the rule. | 05-09-2013 |
20130179937 | SECURITY MODEL ANALYSIS - A customized security model template is created that is customized for a specific organization's security related procedures. The customized security model template is instantiated with parameters associated with the organization to create an instantiated security model, and a report is produced based on simulations of the instantiated security model that specifies metrics of the organization's security implementation. | 07-11-2013 |
20130179974 | INFERRING A STATE OF BEHAVIOR THROUGH MARGINAL PROBABILITY ESTIMATION - Systems, computer-readable media storing instructions, and methods can infer a state of behavior. Such a method can include constructing a graph including nodes representing hosts and domains based on an event dataset. The graph can be seeded with information external to the event dataset. A belief whether each of the nodes is in a particular state of behavior can be calculated based on marginal probability estimation. | 07-11-2013 |
20130194636 | DOCUMENT CERTIFICATES - In one implementation, a physical version of a document is converted to a digital representation of the physical version and a new certificate is computed for the digital representation of the physical version. The new certificate is computed based on the digital representation of the physical version, at least one processing step performed on the digital representation, and a prior certificate computed for a prior digital representation indicative of the physical version. In another implementation, a document is validated. | 08-01-2013 |
20130290356 | SUBMATCH EXTRACTION - A method for submatch extraction may include receiving an input string, receiving a regular expression. The method may further include converting the regular expression with capturing groups into ordered binary decision diagrams (OBDDs) to extract submatches. | 10-31-2013 |
20140040261 | INPUT PARTITIONING AND MINIMIZATION FOR AUTOMATON IMPLEMENTATIONS OF CAPTURING GROUP REGULAR EXPRESSIONS - A method for submatch extraction may include receiving an input string, receiving a regular expression, and converting the regular expression with capturing groups into a plurality of finite automata to extract submatches. The method further includes using a first automaton to determine whether the input string is in a language described by the regular expression, and to process the input string, and using states of the first automaton in a second automaton to extract the submatches. In addition, input partitioning and automaton minimization techniques may be employed to reduce the storage area consumed by the plurality of finite automata. | 02-06-2014 |
20140090056 | SECURITY ALERT PRIORITIZATION - In one implementation, a security alert prioritization system identifies a host and a domain associated with a security alert that was generated in response to a communication between the host and the domain. The security alert prioritization system accesses a security state associated with the host and a security state associated with the domain, and compute a priority of the security alert based on the security state associated with the host and the security state associated with the domain. | 03-27-2014 |
20140213293 | Authenticating a User's Location in a Femtocell-Based Network - A method for authenticating a user's location in a femtocell-based network is disclosed. A user is associated to a femtocell connected to a connection point in the wireless network. An indication of the user's location is provided to a remote user. A characteristic of a connection between the femtocell and the connection point is monitored. The monitored characteristic is provided to the remote user to verify user's location. | 07-31-2014 |
20140215607 | THREAT EXCHANGE INFORMATION PROTECTION - Threat exchange information protection can include receiving security information from a number of participants of a threat exchange community, wherein a portion of the received security information is encoded with pseudonyms by each of the number of participants, analyzing the security information collectively from the number of participants, wherein the portion of the received security information remains encoded, and sending analysis results to each of the number of participants, wherein the analysis results include information relating to the portion. | 07-31-2014 |
20140372105 | Submatch Extraction - A method for submatch extraction may include receiving an input string, receiving a regular expression, and converting the regular expression with capturing groups into a plurality of finite automata to extract submatches. The method further includes using a first automaton to determine whether the input string is in a language described by the regular expression, and to process the input string, and using states of the first automaton in a second automaton to extract the submatches. | 12-18-2014 |
Patent application number | Description | Published |
20100161681 | METHODS, SYSTEMS, AND COMPUTER PROGRAM PRODUCTS FOR DATABASE TABLE AGGREGATION - Methods, systems, and computer program products for database table aggregation are provided. A method includes encoding first and second components via a waveform definition, the first and second components specifying first and second criteria, respectively, for aggregating data. The method includes generating a complex periodic aggregation waveform (CPAW) having variable-sized square waves representing the components in a repeating pattern corresponding to the definition and the criteria, and which spans a first axis. The method includes providing a maximum byte count for aggregated data stored in a table defined by the first and/or second criteria, aggregating the data in accordance with the criteria, and creating a new table for overflow of data determined for the table when the maximum byte count is exceeded. The method includes updating the CPAW with results of the aggregation and generating a waveform representing the new table along a second axis. | 06-24-2010 |
20120323974 | METHODS, SYSTEMS, AND COMPUTER PROGRAM PRODUCTS FOR DATABASE TABLE AGGREGATION - Database table aggregation is implemented by a method that includes encoding first and second components via a waveform definition, the first and second components specifying criteria for aggregating data. The method also includes generating a complex waveform representing the components in a pattern corresponding to the waveform definition and criteria, which spans a first axis indicative of a time period for aggregating the data. The method further includes providing a byte count for aggregated data stored in a first table defined by the criteria, aggregating the data for the time period, and creating a second table for overflow data when the count is exceeded. The method also includes updating the complex waveform to reflect results of the aggregation that includes generating a waveform representing the second table along a second axis depicted at a location corresponding to a time in which the data aggregation for the first table was initiated. | 12-20-2012 |
20140059090 | METHODS, SYSTEMS, AND COMPUTER PROGRAM PRODUCTS FOR DATABASE TABLE AGGREGATION - Database table aggregation is implemented by a method that includes encoding first and second components via a waveform definition, the first and second components specifying criteria for aggregating data, and the first component is defined to provide data aggregation at a higher granularity than the second component. The method also includes generating a complex waveform representing the components in a pattern corresponding to the waveform definition and criteria, which spans a first axis indicative of a time period for the aggregation. The method includes providing a byte count for aggregated data stored in a first table defined by the criteria, aggregating the data for the time period, and updating the complex waveform to reflect results of the aggregation that includes generating a waveform representing a second table along a second axis depicted at a location corresponding to a time in which the data aggregation for the first table was initiated. | 02-27-2014 |
Patent application number | Description | Published |
20100021532 | Personal care composition containing yeast/polyphenol ferment extract - Disclosed is a yeast/polyphenol ferment extract, and a personal care composition including the yeast/polyphenol ferment extract. Also disclosed is a method for preparing and using the yeast/polyphenol extract and the personal care composition. | 01-28-2010 |
20120121522 | METABOLIZED CONDITIONED GROWTH MEDIUM AND METHODS OF USE - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 05-17-2012 |
20130101576 | COMPOSITION CONTAINING AN EXTRACT OF A SEQUENTIAL OR SIMULTANEOUS FERMENTATION - Disclosed herein is a topical composition that contains a fermentation extract from a simultaneous or sequential fermentation. When topically applied to skin, the composition of the invention is effective in stimulating the production of hyaluronic acid, CD44 and Caspase 14 protein in skin cells. | 04-25-2013 |
20140037675 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 02-06-2014 |
20140037676 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 02-06-2014 |
20140037677 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 02-06-2014 |
20140038256 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 02-06-2014 |
20140045240 | PROCESS FOR PREPARING METABOLIZED CONDITIONED GROWTH MEDIA - Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition. | 02-13-2014 |
Patent application number | Description | Published |
20090220598 | Stable Oral Pharmaceutical Composition Containing Thyroid Hormone Receptor Agonists - Compositions are described in which certain thyroid hormone receptor-binding compounds are formulated together with either an enteric coating, an antioxidant, or both an enteric coating and an antioxidant. Such formulation acts to prevent the formation of undesired reaction products in vivo. | 09-03-2009 |
20130224296 | Drug Formulations Using Water Soluble Antioxidants - The present invention relates to solid, semisolid, or liquid formulations comprising water soluble antioxidants that prevent or reduce formic acid and/or formyl species generation in the dosage form during the manufacturing process and/or during shelf-life storage. The formulations of the present invention prevent or reduce formation of N-formyl impurities (and gelatin cross-linking) during the manufacturing process and/or during shelf-life storage. | 08-29-2013 |
20130296325 | HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TR- IAZIN-6-YLOXY]-1-METHYLETHYL ESTER - The present invention is directed to a high drug load tablet formulation of [(1R),2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester, and to methods of using the formulation in the treatment of cancer. The tablet is obtained by means of a wet granulation process. | 11-07-2013 |
20150297603 | HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TR- IAZIN-6-YLOXY]-1-METHYLETHYL ESTER - The present invention is directed to a high drug load tablet formulation of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester, and to methods of using the formulation in the treatment of cancer. | 10-22-2015 |